A Phase 1 Randomized Double-Blind Positive-Controlled Ascending Dose Study to Evaluate the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4 Anthrax Vector Candidate Vaccines - Ad4-PA (Protective Antigen)and Ad4-PA-GPI (Glycosylphosphatidylinositol)
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2018
Price : $35 *
At a glance
- Drugs Anthrax vaccine (Primary)
- Indications Anthrax
- Focus Adverse reactions
- Sponsors PaxVax
- 28 Jun 2018 Status changed from active, no longer recruiting to completed.
- 25 Jul 2014 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 25 Jul 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov record.